Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC.ALNY · Entity 3132 | Director | June 01, 2026 | June 03, 2026 |
| KYNTRA BIO, INC.FGEN · Entity 7431 | Director | June 05, 2024 | June 07, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ALNYLAM PHARMACEUTICALS, INC.
Report date June 01, 2026 · Filed June 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $295.63 · Expires 2036-06-01 | Direct | 4,393 |
Reported balance
After 2026-06-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-01 · Grant · Acquired 4,393 · Balance 4,393 F1: The stock option will vest as to one third of the shares on each of the first, second and third anniversaries of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option will vest as to one third of the shares on each of the first, second and third anniversaries of the date of grant.
KYNTRA BIO, INC.
Report date June 05, 2024 · Filed June 07, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.21 · Expires 2034-06-04 | Direct | 70,000 |
Reported balance
After 2024-06-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-06-05 · Grant · Acquired 70,000 · Balance 70,000 F1: Options vest on the earlier of June 16, 2025 or the date of the next annual meeting of stockholders, subject to the reporting person's continuous service on the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Options vest on the earlier of June 16, 2025 or the date of the next annual meeting of stockholders, subject to the reporting person's continuous service on the applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 01, 2026 Filed Jun 3, 2026 20:23 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantStock Option (Right to Buy) · Derivative | 4,393 | $0.00 Strike: $295.63 | $0.00 |
DisclosureSEC source: 0001178670-26-000047 · form4.xml · derivative · entry 1 Cravatt Benjamin · CIK 0001819573 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,393 Underlying: Common Stock · 4,393 shares Expires 2036-06-01 F1 · derivative.exercise_date: The stock option will vest as to one third of the shares on each of the first, second and third anniversaries of the date of grant. Read SEC document |
| June 05, 2024 Filed Jun 7, 2024 00:00 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | GrantStock Option (Right to Buy) · Derivative | 70,000 | $0.00 Strike: $1.21 | $0.00 |
DisclosureSEC source: 0001415889-24-015855 · form4-06062024_080607.xml · derivative · entry 1 Cravatt Benjamin · CIK 0001819573 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2034-06-04 F1 · derivative.exercise_date: Options vest on the earlier of June 16, 2025 or the date of the next annual meeting of stockholders, subject to the reporting person's continuous service on the applicable vesting date. Read SEC document |
| June 09, 2023 Filed Jun 9, 2023 23:56 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 2,178 | $17.51 | $38,136.78 |
DisclosureSEC source: 0001209191-23-036081 · doc4.xml · nonDerivative · entry 3 Cravatt Benjamin · CIK 0001819573 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,736 F2 · shares: Represents the number of shares sold by the reporting person (pursuant to a 10b5-1 trading plan dated March 2, 2023) to cover the tax obligation realized upon the vesting of restricted stock units previously reported in Table I. F4 · price: Price reported is a weighted-average sales price. The shares were sold at prices ranging from $17.40 to $17.72. The Reporting Person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 09, 2023 Filed Jun 9, 2023 23:56 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | SaleCommon Stock | 1,766 | $16.75 | $29,580.50 |
DisclosureSEC source: 0001209191-23-036081 · doc4.xml · nonDerivative · entry 2 Cravatt Benjamin · CIK 0001819573 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 30,914 F2 · shares: Represents the number of shares sold by the reporting person (pursuant to a 10b5-1 trading plan dated March 2, 2023) to cover the tax obligation realized upon the vesting of restricted stock units previously reported in Table I. F3 · price: Price reported is a weighted-average sales price. The shares were sold at prices ranging from $16.16 to $17.13. The Reporting Person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| June 07, 2023 Filed Jun 9, 2023 23:56 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | GrantStock Option (Right to Buy) · Derivative | 12,666 | $0.00 Strike: $17.13 | $0.00 |
DisclosureSEC source: 0001209191-23-036081 · doc4.xml · derivative · entry 4 Cravatt Benjamin · CIK 0001819573 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,666 Underlying: Common Stock · 12,666 shares Expires 2033-06-06 F5 · derivative.exercise_date: Options vest on the earlier of June 7, 2024 or the date of the next annual meeting of stockholders, subject to the reporting person's continuous service on the applicable vesting date. Read SEC document |
| June 07, 2023 Filed Jun 9, 2023 23:56 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | GrantCommon Stock | 8,289 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-036081 · doc4.xml · nonDerivative · entry 1 Cravatt Benjamin · CIK 0001819573 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,680 F1 · shares: Represents the grant of restricted stock units that vest on the earlier of June 7, 2024 or the date of the next annual meeting of stockholders, subject to the reporting person's continuous service on the applicable vesting date. Read SEC document |
| June 16, 2022 Filed Jun 22, 2022 01:10 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | GrantStock Option (Right to Buy) · Derivative | 25,684 | $0.00 Strike: $9.00 | $0.00 |
DisclosureSEC source: 0001209191-22-038606 · doc4.xml · derivative · entry 2 Cravatt Benjamin · CIK 0001819573 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,684 Underlying: Common Stock · 25,684 shares Expires 2032-06-15 F2 · derivative.exercise_date: Options vest on the earlier of June 16, 2023 or the date of the next annual meeting of stockholders, subject to the reporting person's continuous service on the applicable vesting date. Read SEC document |
| June 16, 2022 Filed Jun 22, 2022 01:10 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | GrantCommon Stock | 15,777 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-038606 · doc4.xml · nonDerivative · entry 1 Cravatt Benjamin · CIK 0001819573 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,391 F1 · shares: Represents the grant of restricted stock units that vest on the earlier of June 16, 2023 or the date of the next annual meeting of stockholders, subject to the reporting person's continuous service on the applicable vesting date. Read SEC document |
| May 26, 2021 Filed May 28, 2021 23:02 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | GrantStock Option (Right to Buy) · Derivative | 7,800 | $0.00 Strike: $20.86 | $0.00 |
DisclosureSEC source: 0001209191-21-036671 · doc4.xml · derivative · entry 2 Cravatt Benjamin · CIK 0001819573 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,800 Underlying: Common Stock · 7,800 shares Expires 2031-05-25 F2 · derivative.exercise_date: Options vest on the earlier of May 26, 2022 or the date of the next annual meeting of stockholders, subject to the reporting person's continuous service on the applicable vesting date. Read SEC document |
| May 26, 2021 Filed May 28, 2021 23:02 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | GrantCommon Stock | 4,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-036671 · doc4.xml · nonDerivative · entry 1 Cravatt Benjamin · CIK 0001819573 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,614 F1 · shares: Represents the grant of restricted stock units that vest on the earlier of May 26, 2022 or the date of the next annual meeting of stockholders, subject to the reporting person's continuous service on the applicable vesting date. Read SEC document |
| August 05, 2020 Filed Aug 7, 2020 23:50 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | GrantStock Option (Right to Buy) · Derivative | 10,400 | $0.00 Strike: $42.65 | $0.00 |
DisclosureSEC source: 0001209191-20-045770 · doc4.xml · derivative · entry 3 Cravatt Benjamin · CIK 0001819573 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,400 Underlying: Common Stock · 10,400 shares Expires 2030-08-05 F3 · derivative.exercise_date: Option vests quarterly over three years from August 5, 2020. Read SEC document |
| August 05, 2020 Filed Aug 7, 2020 23:50 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | GrantStock Option (Right to Buy) · Derivative | 6,496 | $0.00 Strike: $42.65 | $0.00 |
DisclosureSEC source: 0001209191-20-045770 · doc4.xml · derivative · entry 2 Cravatt Benjamin · CIK 0001819573 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,496 Underlying: Common Stock · 6,496 shares Expires 2030-08-05 F2 · derivative.exercise_date: Options vest on the earlier of June 4, 2021 or the date of the next annual meeting of stockholders, subject to the reporting person's continuous service on the applicable vesting date. Read SEC document |
| August 05, 2020 Filed Aug 7, 2020 23:50 UTC | KYNTRA BIO, INC. FGEN · Entity 7431 | GrantCommon Stock | 3,914 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-045770 · doc4.xml · nonDerivative · entry 1 Cravatt Benjamin · CIK 0001819573 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,914 F1 · shares: Represents the grant of restricted stock units that vest on the earlier of June 4, 2021 or the date of the next annual meeting of stockholders, subject to the reporting person's continuous service on the applicable vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.